A Phase IIb Efficacy Trial of Ciclosporin (NeuroSTAT) for Moderate to Severe Traumatic Brain Injuries (TBI).

Trial Profile

A Phase IIb Efficacy Trial of Ciclosporin (NeuroSTAT) for Moderate to Severe Traumatic Brain Injuries (TBI).

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Brain injuries
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Sponsors NeuroVive Pharmaceutical
  • Most Recent Events

    • 15 Feb 2018 According to a NeuroVive Pharmaceuticals media release, the proceeds from a successful Rights issue will be used for clinical development and start of this trial in 2018.The company also expects to engage partners and/or receive additional non-diluting funding for this trial
    • 21 Sep 2017 According to a NeuroVive Pharmaceutical AB media release, the EMA Scientific Advice feedback is supportive of the novel design of this trial.
    • 07 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top